CDIOW executed a 1-for-30 reverse stock split while experiencing severe revenue decline (-57.5%) and massive R&D expense surge (+2101.6%), alongside significant asset deterioration.
The reverse stock split combined with plummeting revenues and exploding R&D costs signals a company in financial distress attempting to maintain exchange listing requirements. The dramatic shift from modest R&D spending to $641K suggests either a strategic pivot or loss of cost controls during a period when revenues are collapsing.
The company's financial position deteriorated significantly with revenue falling 57.5% to just $15K while R&D expenses exploded over 2000% to $641K, creating an unsustainable cost structure. Despite the revenue collapse, operating losses actually improved 22.5% to -$6.5M, though this appears driven by the comparison to an even worse prior year. The balance sheet contracted across all major categories with total assets declining 26.8% to $7.8M and stockholders' equity falling 27% to $7.0M, indicating a company burning through cash while struggling to generate meaningful revenue.
R&D investment increased 2101.6% — signals commitment to future product development, though near-term margin impact.
Revenue declined 57.5% — significant demand weakness or market share loss warrants investigation.
Receivables declined — improved collection efficiency or conservative revenue recognition.
Current assets declined 32.6% — monitor working capital adequacy and short-term liquidity.
Equity decreased 27% — buybacks or losses reducing book value, monitor solvency ratios.
Total assets contracted 26.8% — asset sales, write-downs, or balance sheet optimization underway.
Liabilities reduced 25% — deleveraging improves balance sheet strength and financial flexibility.
Operating income improving — cost discipline or growing revenue base absorbing fixed costs.
Net income grew 22.5% — bottom-line growth signals improving overall business health.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →